Clinical trial
Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract…
NCT00490399 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00490399 |
|---|---|
| Title | Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas |
| Official title | A Phase II Trial of GEMZAR Combined With Cisplatin in Patients With Inoperable Biliary Tract Carcinomas |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Biliary Tract Carcinoma |
| Intervention type | Drug |
| Interventions | gemcitabine, cisplatin |
| Enrollment | 39 |
| Start date | Mar 1, 2003 |
| Completion | Sep 1, 2004 |
| First posted | Jun 22, 2007 |
| Last update posted | Jun 22, 2007 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: